International Congress on Targeted Anticancer Therapies 2013

Oncology Meeting Resources

04 Mar - 06 Mar, Paris, France

On this page, ESMO members may download a PDF version of presentations given at TAT 2013 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Search Meeting Resources by Keyword

 

Useful links

Presenter Presentation title Session title
Jean-Charles Soria Opening address by the TAT 2013 Congress President Opening ceremony
Rolf Stahel Welcome address by ESMO´s President-Elect Opening ceremony
Giuseppe Giaccone Welcome address by Chairman TAT 2013 Scientific Advisory Board Opening ceremony
Christiaan Maats Introduction NDDO Honorary Award Lecture 2013 Opening ceremony
Jean-Pierre Armand NDDO Honorary Award Lecture 2013: Phase 1, a critical step for cancer drug development Opening ceremony
Michael B. Atkins Keynote Lecture: Targeting immune checkpoints in cancer therapy (See also Session 2) Opening ceremony
David Feltquate, Nivolumab (BMS-936558): a fully human monoclonal antibody targeting PD-1 New Immune Checkpoints as Drug Targets
James Smothers AMP-224, a fusion protein that targets PD-1 New Immune Checkpoints as Drug Targets
Klas Wiman A first-in-man clinical phase I study with the p53-targeting compound APR-246 in patients with haematological malignancies or prostate cancer Phase I Studies, Completed or in Progress
L. Rhoda Molife PI3K/Akt activation and response in a phase Ib trial of the Akt Inhibitor GDC-0068 with docetaxel or mFOLFOX in refractory solid tumours Phase I Studies, Completed or in Progress
Dirk Strumberg, Marienhospital Herne Antimetastatic activity of Atu027, a liposomal siRNA formulation, targeting protein kinase N3 (PKN3): final results of a phase I study Phase I Studies, Completed or in Progress
M. Maio Immunomodulatory activity of SGI-110, a second generation hypomethylating agent Phase I Studies, Completed or in Progress
Konstantin Dragnev A proof-of-principle histone deacetylase inhibitor trial in resectable aerodigestive tract cancer: Intratumoural drug levels and biomarker responses Phase I Studies, Completed or in Progress
Emile Voest Tumour heterogeneity: Is it really a problem? Whole-Genome Sequencing in Patient Selection for Targeted Therapies
Jean-Charles Soria WINTHER: A study to select rational therapeutics based on the analysis of tumour and matched normal tissue biopsies in subjects with advanced malignancies Whole-Genome Sequencing in Patient Selection for Targeted Therapies